Autism and Neurodevelopmental Disorders constitute a diverse array of conditions characterized by challenges in communication, social interaction, and repetitive behaviors. Among these, Autism Spectrum Disorder (ASD) stands out as the most recognized, marked by difficulties in social engagement, communication hurdles, and repetitive conduct. ASD's spectrum nature means symptoms and severity levels vary widely among individuals. Beyond ASD, other neurodevelopmental disorders encompass Attention Deficit Hyperactivity Disorder (ADHD), intellectual disabilities, learning disorders, and motor conditions like cerebral palsy. While the precise causes remain elusive, genetics and environment are believed to exert significant influence. Recent genetic advancements have identified various genetic variations linked with autism and related disorders, underscoring the intricate interplay between genetics and environmental factors in their development. Timely diagnosis and intervention are paramount for enhancing outcomes. Behavioral therapies, educational strategies, and sometimes medication can ameliorate symptoms and enhance quality of life. However, access to these interventions varies widely based on socioeconomic status and geographic location. Ongoing research endeavors strive to deepen our comprehension of the underlying mechanisms of these disorders, alongside developing more efficacious treatments and support mechanisms. Promoting greater awareness and acceptance is equally pivotal in fostering inclusivity and support for individuals navigating these conditions.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States